Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents.
Arq Neuropsiquiatr
; 70(10): 799-806, 2012 Oct.
Article
em En
| MEDLINE
| ID: mdl-23060107
ABSTRACT
OBJECTIVE:
It is estimated that circa 50,000 individuals have relapsing-remitting multiple sclerosis in Latin America. European and North-American algorithms for the treatment of multiple sclerosis do not foresee our regional difficulties and the access of patients to treatment.METHODS:
The Latin American Multiple Sclerosis Forum is an independent and supra-institutional group of experts that has assessed the latest scientific evidence regarding efficacy and safety of disease-modifying treatments. Accesses to treatment and pharmacovigilance programs for each of the eight countries represented at the Forum were also analyzed.RESULTS:
A specific set of guidelines based upon evidence-based recommendations was designed for Latin America. Future perspectives of multiple sclerosis treatment were also discussed.CONCLUSIONS:
The present paper translated an effort from representatives of eight countries discussing a matter that cannot be adapted to our region directly from purely European and North-American guidelines for treatment.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Algoritmos
/
Adjuvantes Imunológicos
/
Esclerose Múltipla Recidivante-Remitente
/
Imunossupressores
Tipo de estudo:
Guideline
/
Prognostic_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article